CGRP vs TLQP-21 — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide produced by alternative splicing of the calcitonin gene in neurons. It is the most abundant neuropeptide in the sensory nervous system, expressed in trigeminal ganglion neurons and released from perivascular n...
Calculate CGRP dose →TLQP-21 is a 21-amino acid peptide derived from the C-terminal region of VGF (Nerve Growth Factor-Inducible), a large precursor neuropeptide that is proteolytically cleaved into multiple bioactive fragments. VGF is strongly induced by NGF and BDNF and plays roles in energy homeos...
Calculate TLQP-21 dose →| Parameter | CGRP | TLQP-21 |
|---|---|---|
| Category | Neuropeptide | Neuropeptide |
| Research | FDA Approved (Anti-CGRP antibodies) | Research |
| Half-Life | ~7-10 min (plasma; native) | Unknown |
| Typical Dose | Anti-CGRP mAbs: 70-240 mg SC monthly or quarterly | 1-100 nmol (animal) |
| Frequency | Monthly or quarterly (approved antibodies) | Variable |
| Route | Endogenous; IV/SC (research) | Intrathecal, Subcutaneous, Intracerebroventricular |
| FDA Status | Anti-CGRP antibodies approved (erenumab, fremanezumab, galcanezumab, eptinezumab) | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.